Johnson & Johnson (JNJ)vsQuipt Home Medical Corp (QIPT)
JNJ
Johnson & Johnson
$239.93
+1.98%
HEALTHCARE · Cap: $567.22B
QIPT
Quipt Home Medical Corp
$3.65
0.00%
HEALTHCARE · Cap: $162.30M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 35448% more annual revenue ($94.19B vs $264.97M). JNJ leads profitability with a 28.5% profit margin vs -4.0%. JNJ earns a higher WallStSmart Score of 71/100 (B).
JNJ
Strong Buy71
out of 100
Grade: B
QIPT
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.5%
Fair Value
$516.67
Current Price
$239.93
$276.74 discount
Intrinsic value data unavailable for QIPT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Keeps 28 of every $100 in revenue as profit
Strong operational efficiency at 24.0%
Earnings expanding 48.6% YoY
Generating 5.5B in free cash flow
Revenue surging 32.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
Operating margin of 1.5%
ROE of -9.3% — below average capital efficiency
Earnings declined 97.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 28.5% and operating margin at 24.0%.
Bull Case : QIPT
The strongest argument for QIPT centers on Revenue Growth, Price/Book. Revenue growth of 32.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are PEG Ratio.
Bear Case : QIPT
The primary concerns for QIPT are Market Cap, Operating Margin, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while QIPT is a hypergrowth play — different risk/reward profiles.
QIPT carries more volatility with a beta of 0.49 — expect wider price swings.
QIPT is growing revenue faster at 32.0% — sustainability is the question.
JNJ generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (71/100 vs 40/100), backed by strong 28.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Quipt Home Medical Corp
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Quipt Home Medical Corp. The company is headquartered in Wilder, Kentucky.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?